TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment
Relapse in multiple myeloma (MM) decreases therapy efficiency through unclear mechanisms of chemoresistance. Since our group previously demonstrated that heme oxygenase-1 (HO-1) and Toll-like receptor 4 (TLR4) are two signaling pathways protecting MM cells from the proteasome inhibitor bortezomib (B...
Main Authors: | Grazia Scandura, Cesarina Giallongo, Fabrizio Puglisi, Alessandra Romano, Nunziatina Laura Parrinello, Tatiana Zuppelli, Lucia Longhitano, Sebastiano Giallongo, Michelino Di Rosa, Giuseppe Musumeci, Roberto Motterlini, Roberta Foresti, Giuseppe Alberto Palumbo, Giovanni Li Volti, Francesco Di Raimondo, Daniele Tibullo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Antioxidants |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3921/11/4/767 |
Similar Items
-
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells
by: Daniele Tibullo, et al.
Published: (2020-04-01) -
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
by: Dong Liang, et al.
Published: (2024-09-01) -
Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
by: Jianhao Liu, et al.
Published: (2021-12-01) -
Heme Oxygenase-1 Overexpression Promotes Uveal Melanoma Progression and Is Associated with Poor Clinical Outcomes
by: Lucia Longhitano, et al.
Published: (2022-10-01) -
P01: ARGININE STARVATION IN MULTIPLE MYELOMA MICROENVIRONMENT CONVEYS BORTEZOMIB REFRACTORINESS VIA TLR4 PATHWAY.
by: A Romano, et al.
Published: (2022-04-01)